Kardigan, Inc. (NASDAQ: KARD) is a Healthcare company (Biotechnology) with a market capitalization of $1.2B. The Maz Rating grades it against the other companies in its sector.
Kardigan, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $13.19, Kardigan, Inc. trades at 2.1x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -78.0%, return on invested capital of -36.3% and a free cash flow yield of -14.4%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 10.62. Over the past 52 weeks the share price ranged from $12.23 to $27.00, with a beta of 6.05.
Kardigan, Inc. does not currently pay a dividend.
1 Wall Street analyst rating covers the stock: 1 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Kardigan, Inc. (KARD) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.24% / 30% · (Cash+Inv) / Mkt Cap (36m) 38.9% / 30% · Interest income / Revenue 623600000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.24% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 31.1% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 623600000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.24% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 31.1% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 623600000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.43% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 78.9% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 623600000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.57% / 33.33% · (Cash+ST Inv) / Total Assets 72.7% / 33.33% · (Cash+Recv) / Total Assets 72.7% / 33.33% · Interest income / Revenue 623600000.0% / 5% | Fail |
No. As of September 2026, Kardigan, Inc. (KARD) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Kardigan, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 623600000.0% of each dividend: Kardigan, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.